Geremy Thomas, founder and Chief Executive Officer of Sativa Investments, said: “The new Home Office guidelines determining the prescription of Medicinal Cannabis encompass the treatment of pain and nausea in cancer patients. Matthew’s qualifications and research in this area add even further to the input of Sativa’s top-level Medicinal Cannabis Advisory Board. Patient outcome is the clear driver in the highly sensitive and prevalent area of cancer treatment.”
Sativa Investments PLC (NEX: SATI), the UK’s first medicinal cannabis investment vehicle, has appointed Dr Matthew Brown to its Medicinal Cannabis Advisory Board with immediate effect.
Dr Brown is an award-winning Consultant at The Royal Marsden Hospital specialising in pain medicine and anaesthetics and has recently published research into using cannabinoids for cancer pain treatment. Dr Brown holds an honorary research position at the Institute of Cancer Research having completed doctoral research into cancer-related pain at the institution, becoming the first anaesthetist to complete a higher degree in the Institute’s history.
He has lectured on and produced research covering the breadth of cancer-related pain including chemotherapy induced neuropathy, persistent post-surgical pain as well as reducing pain associated with cancer using high-intensity focused ultrasound (HIFU). Dr Brown has won numerous awards throughout his career including the War Memorial Scholarship at King’s College London and the Chairman’s Prize on graduation from The Institute of Cancer Research.
Dr Brown’s training has come from a broad range of medical institutions across the UK. He graduated from King’s College London with distinction in 2004. His clinical training in pain medicine was gained at The Royal National Orthopaedic Hospital and the National Hospital for Neurology and Neurosurgery. Dr Brown’s anaesthetic training was undertaken at the Imperial School of Anaesthesia in London, where he also received a place on the prestigious National Institute for Health Research’s Academic Clinical Fellowship Programme.
As at the date of this announcement, Dr Brown has unapproved share options in the Company over 76,923 shares at a strike price of 6.5p.
